4.8 Article

LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake

Journal

SCIENCE
Volume 317, Issue 5843, Pages 1390-1393

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1147614

Keywords

-

Funding

  1. NIDA NIH HHS [DA019676, R01 DA013261, R01 DA019676, DA013261] Funding Source: Medline
  2. NIDDK NIH HHS [R01 DK053973, R21 DK060841] Funding Source: Medline
  3. NIGMS NIH HHS [U54 GM075026, GM075026, U54 GM095315, R21 GM075936, GM075936] Funding Source: Medline

Ask authors/readers for more resources

Tricyclic antidepressants exert their pharmacological effect-inhibiting the reuptake of serotonin, norepinephrine, and dopamine-by directly blocking neurotransmitter transporters (SERT, NET, and DAT, respectively) in the presynaptic membrane. The drug-binding site and the mechanism of this inhibition are poorly understood. We determined the crystal structure at 2.9 angstroms of the bacterial leucine transporter (LeuT), a homolog of SERT, NET, and DAT, in complex with leucine and the antidepressant desipramine. Desipramine binds at the inner end of the extracellular cavity of the transporter and is held in place by a hairpin loop and by a salt bridge. This binding site is separated from the leucine-binding site by the extracellular gate of the transporter. By directly locking the gate, desipramine prevents conformational changes and blocks substrate transport. Mutagenesis experiments on human SERT and DAT indicate that both the desipramine-binding site and its inhibition mechanism are probably conserved in the human neurotransmitter transporters.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available